Videos

MDS 2017 Treating Movement Disorders With Telemedicine: Getting Started

Treating Movement Disorders With Telemedicine: Getting Started

Jaime Hatcher-Martin, MD, PhD, a movement disorders specialist at Emory University Hospital and the founder of Emory's movement disorders telemedicine clinic, shares her personal experience with telemedicine and provides some guidance for clinicians who might be interested in exploring this treatment option to improve their patients' access to care. Scroll below the video to read the full transcript.

MDS 2017 Using Speech Markers to Identify Cognitive, Motor Deficits in Parkinson's

Using Speech Markers to Identify Cognitive, Motor Deficits in Parkinson's

Kara Smith, MD, a movement disorders specialist at UMass Memorial Medical Center and an assistant professor at the University of Massachusetts Medical School, both in Worcester, discusses how a brief free speech sample might be used to calculate a patient's cognitive and motor scores. Scroll below the video to read the full transcript.

MDS Coverage 2017

MDS 2017 Investigational Therapy Reduces Tourette Tic Severity Without Adverse Effects

Investigational Therapy Reduces Tourette Tic Severity Without Adverse Effects

Nearly 40% of patients in the treatment group were "much" or "very much" improved at 4 weeks.

MDS 2017 Deep Brain Stimulation Reduces Risk of Polypharmacy in Parkinson's

Deep Brain Stimulation Reduces Risk of Polypharmacy in Parkinson's

Patients who underwent deep brain stimulation were 94% less likely to require polypharmacy at 5 years.

MDS 2017 Levodopa May Benefit Heart Health in Parkinson's Disease

Levodopa May Benefit Heart Health in Parkinson's Disease

Although nonmotor symptoms in Parkinson's have gained significant attention through the years, blood pressure changes have been overlooked.

MDS 2017 Metabolic Syndrome May Have Role in Parkinson's Progression

Metabolic Syndrome May Have Role in Parkinson's Progression

Patients with metabolic syndrome experienced greater worsening of UPDRS scores over time compared with patients without metabolic syndrome.

MDS 2017 Studies Highlight Positive Results for Deutetrabenazine for Tardive Dyskinesia

Studies Highlight Positive Results for Deutetrabenazine for Tardive Dyskinesia

Analyses of the ARM-TD and AIM-TD trials indicate that deutetrabenazine performs better than placebo as treatment for tardive dyskinesia.

MDS 2017 Predicting Mortality in Parkinson's Disease: The Role of Motor Complications

Predicting Mortality in Parkinson's Disease: The Role of Motor Complications

Four-year results show that motor complications, but not burden of nonmotor symptoms, can predict death in patients with Parkinson's disease.

MDS 2017 Neurofilament Light Chain to Predict Progression of Degenerative Brain Disorder

Neurofilament Light Chain to Predict Progression of Degenerative Brain Disorder

Previous research has shown that plasma neurofilament light chain concentration may predict severity of disease progression in progressive supranuclear palsy.

MDS 2017 Gut Microbiota May Play a Role in Progression of Parkinson's Disease

Gut Microbiota May Play a Role in Progression of Parkinson's Disease

New research suggests that baseline gut microbiota may predict the progression of Parkinson's disease at 2 years.

MDS 2017 Polyneuropathy May Signify More Severe Parkinson's Disease

Polyneuropathy May Signify More Severe Parkinson's Disease

While polyneuropathy is fairly common in Parkinson's disease, the etiology of the pain condition is not clear.

MDS 2017 High Total Cholesterol Linked to Decreased Risk of Parkinson's Disease

High Total Cholesterol Linked to Decreased Risk of Parkinson's Disease

Researchers sought to better understand the potential role of cholesterol in the etiology of Parkinson's disease.

Upcoming Meetings

Sign Up for Free e-newsletters